Lucira Health, Inc. (LHDX)
Chart Events
Performance Outlook
| Previous Close | 1.8600 |
| Open | 1.8400 |
| Bid | 1.7700 x 2200 |
| Ask | 1.9600 x 1000 |
| Day's Range | 1.8095 - 1.9200 |
| 52 Week Range | 1.3600 - 11.1000 |
| Volume | |
| Avg. Volume | 89,942 |
| Market Cap | 72.958M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.8930 |
| Earnings Date | Nov 11, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- Motley Fool
Lucira Health, Inc. (LHDX) Q1 2022 Earnings Call Transcript
Earlier today, Lucira Health released financial results for the first quarter ended March 31, 2022. Joining me on today's call are Erik Engelson, president and chief executive officer; and Dan George, chief financial officer.
- GlobeNewswire
Lucira Health Announces First Quarter 2022 Results and Business Update
EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (Nasdaq: LHDX) (“Lucira Health,” “Lucira” or the “Company”), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results and provided business updates for the first quarter ended March 31, 2022. Recent Highlights Achieved net revenue of $90.5 million for the first quarter of 2022, equivalent to 97% of fiscal year 20
- MarketWatch
Lucira Health files for FDA authorization of first COVID-19 & flu at-home molecular test
Lucira Health Inc. said Thursday it has filed for Food and Drug Administration authorization for its first-of-its-kind COVID-19 & flu at-home molecular test. The medical tech company, which went public in February of 2021, specializes in single-use test kits for respiratory diseases. "The request is for prescription at-home use of the PCR-quality test for those with suspected COVID-19 or Influenza," the company said in a statement. The company is hoping to get authorized ahead of the fall and wi
